Drug Profile


Alternative Names: 524W91; BW-524W91; Coviracil; Emtriva; FTC

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Emory University
  • Developer Gilead Sciences
  • Class Antiretrovirals; Deoxyribonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV infections
  • No development reported Hepatitis B

Most Recent Events

  • 20 Feb 2017 Blueclinical initiates enrolment in a phase II trial for HIV infections (Combination therapy) in Portugal (EudraCT2016-000346-61)
  • 13 Feb 2017 Gilead Sciences completes a phase-II trial in HIV infections (In adolescents, In children, In infants) in South Africa (PO, Liquid) (PO, Capsule) (NCT00743340)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top